Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI130 in unresectable locally advanced or metastatic solid tumors (Phase I/II)
CTR20240978Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- May 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of IBI-130 in Nonhematologic neoplasms (9 arms), sponsored by InnoCare Pharma. Primary endpoints: Dose-limiting toxicity (DLT) incidence to determine MTD and/or RP2D and Safety profile (AEs, laboratory tests, physical examinations, vital signs). Started May 2024; status: active.
02
Drugs
IBI-130
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20240978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240978.